---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-077950"
form_type: "8-K"
ticker: "RPRX"
cik: "0001802768"
company_name: "Royalty Pharma plc"
filed_at: "2025-04-10T23:59:59+00:00"
generated_at: "2026-05-23T17:24:13.531151+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Royalty Pharma appoints Vlad Coric, M.D., to Board of Directors effective April 7, 2025.

## Summary
- Dr. Vlad Coric appointed to Royalty Pharma Board effective April 7, 2025.
- He is Chairman and CEO of Biohaven, led Nurtec ODT approval and $13B sale to Pfizer.
- Coric will stand for election at 2025 Annual Meeting; if elected, expected to join Compensation Committee.
- Board determined Coric meets Nasdaq independence standards; will receive standard independent director compensation.

## SEC filing metadata
- accession: 0001193125-25-077950
- form_type: 8-K
- ticker: RPRX
- cik: 0001802768
- company_name: Royalty Pharma plc
- filed_at: 2025-04-10T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802768/000119312525077950/0001193125-25-077950-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802768/000119312525077950/d943352d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-077950
- JSON: https://secwatch.observer/filing/0001193125-25-077950.json
- Plain text: https://secwatch.observer/filing/0001193125-25-077950.txt

## Key facts
- Executive change
  Vlad Coric was appointed as Director at Royalty Pharma plc.
  - Action: appointed
  - Role: Director
  source text: Effective April 7, 2025, Dr. Vlad Coric was appointed to serve as a new member of the Board of Directors (the “Board”) of Royalty Pharma plc (the “Company”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1802768/000119312525077950/0001193125-25-077950-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.